Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Histologically confirmed metastatic adenocarcinoma of the colon or rectum for which no further standard chemotherapy is considered to be effective. Patients must have failed 5-FU, CPT-11 and/or oxaliplatin based chemotherapy. * SWOG performance status 0-1 * ANC\>1000, platelets \>100,000. * Total bilirubin \< 2 x upper limit of normal. Transaminase (AST and/or ALT) \< 2 x upper limit of normal or \< 5 x upper limit of normal in patients with liver metastasis. * Serum creatinine \< 1.25 x institutional upper limit of normal. * Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Exclusion Criteria: * Patient has received any other investigational agent within 28 days of first day of study drug dosing. * History of another malignancy within 3 years prior to study entry, except curatively treated non-melanoma skin cancer, prostate cancer, or cervical cancer in situ. * Patient has another severe and/or life-threatening medical disease. * Patient has an acute or known chronic liver or kidney disease (e.g., chronic active hepatitis, cirrhosis, chronic renal insufficiency). * Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. * Patient has received chemotherapy within 4 weeks (6 weeks for nitrosourea, mitomycin-C or any antibody therapy) * Patients with symptomatic brain metastasis. * Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (e.g. congestive heart failure, myocardial infarction within 6 months of study) * Medical, social or psychological factors interfering with compliance. * Patients who have undergone major surgery for any cause less than 4 weeks prior to study entry. * Patients taking Coumadin® or other agents containing warfarin, with the exception of low dose Coumadin® (1 mg or less) administered prophylactically for maintenance of in-dwelling lines or ports. * Any peripheral neuropathy \> Grade 1. * Patients with unresolved diarrhea \> Grade 1. * Patients may not have a history of an allergy to sulfonamide drugs. * Patients may not have active peptic ulcer disease or other contraindications to chronic NSAID use or aspirin use. * Patients with lactose intolerance. * Patients taking full-dose NSAIDs, including aspirin, regularly for any reason (e.g., arthritis,history of TIA or myocardial infarction). Patients taking cardiac preventive dose ASA (\<81mg daily) are eligible. Patients should stop taking any other NSAIDs 14 days prior to receiving first dose of Celecoxib. * Patients with hypersensitivity to COX-2 inhibitors, NSAIDS or salycilate. * Patients taking fluconazole or lithium.